secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2021-10-18T23:59:59+00:00
Accession:  0001213900-21-053303
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics CMO Departs; Jathin Bandari Named Interim CMO
------------------------------------------------------------------

- Martín Sebastian Olivo, M.D., left as Chief Medical Officer effective Oct 15, 2021; will serve as consultant through Nov 22, 2021.
- Jathin Bandari, M.D., promoted to VP, Head of Clinical Development and Interim Chief Medical Officer.
- Severance includes nine months base salary lump sum, pro-rata bonus, COBRA reimbursement, and pro-rata equity vesting.
- Dr. Bandari joined Protara in April 2020; is a urologic oncologist with fellowship at University of Pittsburgh Medical Center.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021053303/0001213900-21-053303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021053303/ea149033-8k_protarathera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-053303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer